statement
IMVT-1402 in refractory rheumatoid arthritis achieved statistical significance in the Period 2 ACR20 response rate, with the 600mg group meeting key endpoints at week 28 on both ACR20 and ACR50 versus placebo.
A statement by 현대차증권 제약/바이오/의료기기 김현석. Statements are as reported by the cited publishers — not verified by DecisionGateway.
IMVT-1402의 난치성 류마티스관절염 Period 2 탑라인 결과 발표. IMVT-1402 600mg 투여군은 28주차 ACR20과 ACR50에서 모두 고용량군이 위약군 대비 통계적 유의성을 달성해 주요 평가지표 충족
Related claims
Immunovant's Phase 2b trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) demonstrated excellent efficacy and safety, securing the validity of the development strategy.report author · statementIn the 600mg high-dose maintenance group, the ACR20 response rate was 92.5%, with nearly all patients maintaining response through week 28.현대차증권 제약/바이오/의료기기 김현석 · statementThe 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementIMVT-1402 is designed so its binding epitope does not compete with albumin, allowing high-dose continuous administration without hypercholesterolemia concerns, whereas Batoclimab requires dose reduction after several weeks.하나증권 제약/바이오 김선아 · statementFollowing the D2T RA clinical success, the risk discount is reduced from 50% to 40%, leading to a revaluation of IMVT-1402.report author · statementIMVT-1402 is the first clinical case to demonstrate that continuous high-dose dosing is possible without the hypercholesterolemia concerns seen with Batoclimab.report author · statement